A Comparative Study of the Management of Stage 2 hypertension by Combined therapy with Losartan, Amlodipine and Hydrochlorothiazide

AuthorReza Jafarzadeh Esfehanien
AuthorAzadeh Mahmoodi Gharaien
AuthorAli Jafarzadeh Esfehanien
AuthorAfsaneh Rezaie Kalaten
AuthorFaezeh Abbasien
AuthorMajid Jalalyazdien
Issued Date2012-09-30en
AbstractBackground: The most effective and accurate treatment of hypertensive patients reduces cardiovascular events and improves the quality of life. Objective: This study compared the efficacy and safety of combined (combination therapy) with an angiotensin-receptor blocker (ARB) a calcium-channel blocker (CCB) (Losartan / Amloidipine 50/10mg) vs maximal combination doses of ARB with hydrochlorothiazide (Losartan /HCTZ 100/25 mg) and maximal combination doses of CCB with HCTZ (Amlodipine /HCTZ 10/25 mg) in the management of stage 2 hypertension. Methods: This randomized clinical trial (RTC) comprised 478 hypertensive patients with mean age 50.5±5.21 years, and took place between January 2010 and December 2011 in Vasei Hospital clinic in Sabzevar. Antihypertensive drugs were washed out after 5 days of discontinuation of drugs and the patients with mean blood pressure in sitting position ≥ 160 anden
DOIhttps://doi.org/en
URIhttps://brieflands.com/journals/ircrj/articles/12801en
KeywordAngiotensin Receptor Blockeren
KeywordCalcium Channel Blockeren
KeywordHypertensionen
PublisherBrieflandsen
TitleA Comparative Study of the Management of Stage 2 hypertension by Combined therapy with Losartan, Amlodipine and Hydrochlorothiazideen
TypeResearch Articleen

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
icrj-06-79.pdf
Size:
908.51 KB
Format:
Adobe Portable Document Format
Description:
Article/s PDF